IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 801–900 of 1,011
O’Meara, T. A., Marczyk, M., Qing, T., Yaghoobi, V., Blenman, K., Cole, K. S., Pelekanou, V., Rimm, D. L., & Pusztai, L. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00350 · Cited by 59
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Ngo, C., & Postel-Vinay, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030650 · Cited by 57
Swain, S. M., Tang, G., Brauer, H. A., Goerlitz, D. S., Lucas, P. C., Robidoux, A., Harris, B. T., Bandos, H., Ren, Y., Geyer, C. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0152 · Cited by 56
Crosby, E. J., Acharya, C. R., Haddad, A.-F., Rabiola, C. A., Lei, G., Wei, J.-P., Yang, X., Wang, T., Liu, C.-X., Wagner, K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0389 · Cited by 55
Sun, C., Chen, Y.-C., Martinez Zurita, A., Baptista, M. J., Pittaluga, S., Liu, D., Rosebrock, D., Gohil, S. H., Saba, N. S., Davies-Hill, T., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2021006941 · Cited by 54
Barone, B., Calogero, A., Scafuri, L., Ferro, M., Lucarelli, G. T., Zazzo, E. D., Sicignano, E., Falcone, A., Romano, L., Luca, L. D., et al. (2022) · Cancers · doi:10.3390/cancers14102545 · Cited by 55
Tsai, K. K., Huang, S., Northey, J. J., Liao, W., Hsu, C., Cheng, L., Werner, M. E., Chuu, C., Chatterjee, C., Lakins, J. N., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00375-0 · Cited by 59
Bie, N., Yong, T., Wei, Z., Liang, Q., Zhang, X., Li, S., Li, X., Li, J., Gan, L., & Yang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01658-3 · Cited by 53
Unal, B., Kuzu, O. F., Jin, Y., Osorio, D., Kildal, W., Pradhan, M., Kung, S. H. Y., Oo, H. Z., Daugaard, M., Vendelbo, M. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53039-1 · Cited by 59
Kroon, P., Frijlink, E., Iglesias‐Guimarais, V., Volkov, A., van Buuren, M. M., Schumacher, T. N., Verheij, M., Borst, J. G., & Verbrugge, I. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0654 · Cited by 52
“Therefore, this approach is likely to be most effective as standalone treatment for immunogenic cancers in which T cells have already infiltrated the tumor (Ayers et al., 2017).”
BackgroundRNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy
Lau, D., Bobe, A. M., & Khan, A. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.006 · Cited by 55
Butner, J. D., Elganainy, D., Wang, C. X., Wang, Z., Chen, S., Esnaola, N. F., Pasqualini, R., Arap, W., Hong, D. S., Welsh, J. W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay6298 · Cited by 59
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Claps, M., Mennitto, A., Guadalupi, V., Sepe, P., Stellato, M., Zattarin, E., Gillessen, S., Sternberg, C. N., Berruti, A., de Braud, F., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102057 · Cited by 54
Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy
Zhai, W., Zhou, X., Zhai, M., Li, W., Ran, Y., Sun, Y., Du, J., Zhao, W., Xing, L., Qi, Y., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1740-8 · Cited by 53
Jain, K. K. (2020) · Medical Principles and Practice · doi:10.1159/000511107 · Cited by 55
Young, K., Lawlor, R. T., Ragulan, C., Patil, Y., Mafficini, A., Bersani, S., Antonello, D., Mansfield, D., Cingarlini, S., Landoni, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321016 · Cited by 58
“36 Overall, our study provides insights into the heterogeneity of the immune microenvironment in PanNETs and highlights various potential immunotherapeutic targets.”
Epigenetic state determines inflammatory sensing in neuroblastoma
Wolpaw, A. J., Grossmann, L. D., Dessau, J. L., Dong, M. M., Aaron, B., Brafford, P. A., Volgina, D., Pascual‐Pasto, G., Rodríguez-García, A., Uzun, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102358119 · Cited by 55
“Indeed, lower baseline inflammatory signaling has also been associated with ICB resistance (4, 5), and response can be restored in some tumor models by activating tumor cell inflammatory signaling (6, 7).”
BackgroundCai, M., Zhao, X., Cao, M., Ma, P., Chen, M., Wu, J., Jia, C., He, C., Fu, Y., Tan, L., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5435 · Cited by 58
Liu, Z., Xu, H., Weng, S., Ren, Y., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828330 · Cited by 67
“A high TIDE score suggests a worse immunotherapeutic efficacy, while a high Tcell-inflamed GEP indicates an increasing tendency to benefit from PD-1 blockade (30, 31).”
BackgroundAnagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 54
Lin, Z., Huang, K., Guo, H., Jia, M., Liu, X., 孙秋芹, Chen, X., Wu, J., Yao, Q., Zhang, P., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114567 · Cited by 62
Das, A., Fernandez, N. R., Levine, A., Bianchi, V., Stengs, L. K., Chung, J., Negm, L., Dimayacyac, J. R., Chang, Y., Nobre, L. F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0559 · Cited by 55
Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census
Wei, C., Ma, Y., Wang, M., Wang, S., Yu, W., Dong, S., Deng, W., Bie, L., Zhang, C., Shen, W., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00660-4 · Cited by 63
Ye, B., Jiang, A., Feng, L., Wang, C., Liang, X., & Zhang, P. (2024) · BioFactors · doi:10.1002/biof.2142 · Cited by 58
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Cristina, V., Gómez, R. G. H., Szturz, P., Espeli, V. G., & Siano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215399 · Cited by 55
“In the KEYNOTE-012 and KEYNOTE-055 trials, GEP was shown to be a predictive marker for checkpoint inhibitor response with benefits in PFS and OS regardless of viral status [72].”
BackgroundMethodBosisio, F. M., Antoranz, A., van Herck, Y., Bolognesi, M. M., Marcelis, L., Chinello, C., Wouters, J., Magni, F., Alexopoulos, L., Stas, M., et al. (2020) · eLife · doi:10.7554/elife.53008 · Cited by 54
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
Calagua, C., Ficial, M., Jansen, C. S., Hirz, T., del Balzo, L., Wilkinson, S. C., Lake, R. G., Ku, A. T., Voznesensky, O. S., Sykes, D. B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0121 · Cited by 56
“exposure (21,22), and spatial distribution of TILs has identified three distinct cancer immune phenotypes: immune-excluded, immune-desert, and immune-inflamed (21).”
BackgroundRajakumar, T., Horos, R., Jehn, J., Schenz, J., Muley, T., Pelea, O., Hofmann, S., Kittner, P., Kahraman, M., Heuvelman, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00262-y · Cited by 63
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Zemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 55
Maul, J., Guillet, C., Oschmann, A., Maul, L. V., Meier-Schiesser, B., Stadler, P., French, L. E., & Kerl, K. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18879 · Cited by 53
Mao, Y., Xie, H., Lv, M., Yang, Q., Shuang, Z., Gao, F., Li, S., Zhu, L., & Wang, W. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03441-3 · Cited by 62
Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner
Warde, K. M., Smith, L., Liu, L., Stubben, C., Lohman, B. K., Willett, P. W., Ammer, J. L., Castaneda-Hernandez, G., Imodoye, S. O., Zhang, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00420-2 · Cited by 52
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Liu, Y., Liu, Z., Yang, Y., Sun, J., Sun, J., & Liu, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02321-y · Cited by 58
Reschke, R., Enk, A. H., & Hassel, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126532 · Cited by 59
“Similarly, CCL5 transcripts are integrated into the T cell-inflamed gene expression signature, which suggests a benefit for checkpoint therapy [3].”
BackgroundMorris, J., Gonzales, C. B., Chapa, J. J. D. L., Cabang, A. B., Fountzilas, C. K., Patel, M., Orozco, S., & Wargovich, M. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00890 · Cited by 54
“This process can be beneficial in adaptive antitumor immune response (56) but can also be immunosuppressive by upregulation of molecules such as IDO1 in the tumor microenvironment (57) or through feedback inhibition which may reduce antitumor activity (58).”
BackgroundThe Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
Wo, Y. J., Gan, A. S. P., Lim, X., Tay, I. S. Y., Lim, S., Lim, J. C. T., & Yeong, J. P.-S. (2019) · Cells · doi:10.3390/cells9010026 · Cited by 53
“However, as the number of patients benefitting from immunotherapy is suboptimal, many studies have focused on discovering novel biomarkers to reliably identify potential responders [3,4] Classification of the immune infiltrates within the tumor microenvironment (TME) would enable more accurate prediction of cancer pro…”
BackgroundBiomarkers predictive of response to pembrolizumab in head and neck cancer
Pfister, D. G., Haddad, R. I., Worden, F. P., Weiss, J., Mehra, R., Chow, L. Q. M., Liu, S. V., Kang, H., Saba, N. F., Wirth, L. J., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5434 · Cited by 56
Self-citationPersonalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Gu, X., Huang, X., Zhang, X., & Wang, C. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75284 · Cited by 57
Yang, M., Miao, Y., Xie, G., Luo, M., Hu, H., Kwok, H. F., Feng, J., & Guo, A. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0249 · Cited by 53
Deng, P., Wang, Z., Chen, J., Liu, S., Yao, X., Liu, S., Liu, L., Yu, Z., Huang, Y., Xiong, Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159628 · Cited by 50
Gray, E. E., Ulrich, M. L., Epp, A., Younan, P. M., Sahetya, D., Hensley, K. M., Allred, S., Huang, L., Hahn, J., Gahnberg, K., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007572 · Cited by 53
Dummer, R., Robert, C., Scolyer, R. A., Taube, J. M., Tetzlaff, M. T., Menzies, A. M., Hill, A., Grob, J., Portnoy, D. C., Lebbé, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03411-x · Cited by 55
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 59
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC
Bullock, B., Kimball, A. K., Poczobutt, J. M., Neuwelt, A. J., Li, H. Y., Johnson, A. M., Kwak, J., Kleczko, E. K., Kaspar, R. E., Wagner, E. K., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900328 · Cited by 54
“…PD-L1 expression on the surface of tumor cells and/or surrounding stromal cells, tumor-in fi ltrating immune cells, and patient smoking status (Ji et al, 2012; Ngiow et al, 2015; Danilova et al, 2016; Gainor et al, 2016; Spranger et al, 2016; Ayers et al, 2017; Corrales et al, 2017).”
Tissue Site and the Cancer Immunity Cycle
Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 59
Munakata, L., Tanimoto, Y., Osa, A., Meng, J., Haseda, Y., Naito, Y., Machiyama, H., Kumanogoh, A., Omata, D., Maruyama, K., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.011 · Cited by 52
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072367 · Cited by 54
Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
Navarrete-Bernal, M. G. C., Cervantes-Badillo, M. G., Martínez‐Herrera, J. F., Lara-Torres, C. O., Gerson-Cwilich, R., Zentella‐Dehesa, A., Ibarra-Sánchez, M. D. J., Esparza‐López, J., Montesinos, J. J., Cortés-Morales, V. A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01206 · Cited by 55
Kang, B. W., & Chau, I. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000791 · Cited by 55
Khouzam, R. A., Rao, R. S. P., Venkatesh, G. H., Zeinelabdin, N. A., Buart, S., Meylan, M., Nimmakayalu, M. A., Terry, S., & Chouaïb, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680435 · Cited by 57
Shah, M. A., Cunningham, D., Metges, J., Cutsem, E. V., Wainberg, Z. A., Elboudwarej, E., Lin, K.-W., Turner, S., Zavodovskaya, M., Inzunza, H. D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003580 · Cited by 54
Characterizing the molecular and immune landscape of canine bladder cancer
Cronise, K. E., Das, S., Hernandez, B. G., Regan, D. P., Dailey, D. D., McGeachan, R. I., Lana, S. E., Page, R. L., Gustafson, D. L., & Duval, D. L. (2021) · Veterinary and Comparative Oncology · doi:10.1111/vco.12740 · Cited by 61
Zhang, N., Zhang, H., Wang, Z., Dai, Z., Zhang, X., Cheng, Q., & Liu, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691811 · Cited by 63
“T cell-inflamed gene expression profile (GEP) was defined through the expression of the 18 genes (28).”
BackgroundLi, M., Hou, X., Sai, K., Wu, L., Chen, J., Zhang, B., Wang, N., Wu, L., Zheng, H., Zhang, J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2059874 · Cited by 54
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
Carroll, T. M., Chadwick, J. A., Owen, R. P., White, M. J., Kaplinsky, J., Peneva, I., Frangou, A., Xie, P. F., Chang, J., Roth, A. J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.006 · Cited by 60
Self-citationGutierrez, M. E., Lam, W., Hellmann, M. D., Gubens, M. A., Aggarwal, C., Tan, D. S. W., Felip, E., Chiu, J. W. Y., Lee, J.-S., Yang, J. C.-H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02385-6 · Cited by 55
Zhang, W., Zhu, Y., Liu, H., Zhang, Y., Liu, H., Adegboro, A. A., Dang, R., Dai, L., Wanggou, S., & Li, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00570-5 · Cited by 53
Bernatowicz, K., Amat, R., Prior, O., Frigola, J., Ligero, M., Grussu, F., Zatse, C., Serna, G., Nuciforo, P. G., Toledo, R. A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009140 · Cited by 53
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy
Darragh, L. B., & Karam, S. D. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00903-x · Cited by 60
Boland, J. L., Zhou, Q. C., Martin, M., Callahan, M. K., Konner, J. A., O'Cearbhaill, R. E., Friedman, C. F., Tew, W. P., Makker, V., Grisham, R. N., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.11.025 · Cited by 57
Emerging therapeutic agents for genitourinary cancers
Zarrabi, K. K., Paroya, A., & Wu, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0780-z · Cited by 51
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
Pérez‐Romero, K., Rodríguez, R. M. A., Amedei, A., Barceló‐Coblijn, G., & Lopez, D. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155521 · Cited by 52
“In general, response to checkpoint inhibitors is better if cancer cells express high levels of immunosuppressive molecules [65,66], in the presence of high levels of inflammatory molecules within the TME [67], or when cancer cells show a high mutational burden and high-level microsatellite instability (MSI-high), caus…”
BackgroundLü, Z., Chen, H., Jiao, X., Zhou, W., Han, W., Li, S., Liu, C. X., Gong, J., Li, J., Zhang, X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000631 · Cited by 52
Ioannou, N., Hagner, P. R., Stokes, M., Gandhi, A. K., Apollonio, B., Fanous, M., Papazoglou, D., Sutton, L., Rosenquist, R., Amini, R., et al. (2020) · Blood · doi:10.1182/blood.2020006073 · Cited by 51
Keenan, T. E., Guerriero, J. L., Barroso‐Sousa, R., Li, T., O’Meara, T. A., Giobbie‐Hurder, A., Tayob, N., Hu, J., Severgnini, M., Agudo, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25769-z · Cited by 54
Du, K., Wei, S., Wei, Z., Frederick, D. T., Miao, B., Moll, T. O. C., Tian, T., Sugarman, E. T., Gabrilovich, D. I., Sullivan, R. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26299-4 · Cited by 52
Ahmed, K. M., Veeramachaneni, R., Deng, D., Putluri, N., Putluri, V., Cardenas, M., Wheeler, D. A., Decker, W. K., Frederick, A. I., Kazi, S. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004752 · Cited by 55
Garassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., Hui, R., Garon, E. B., Horinouchi, H., Sugawara, S., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100431 · Cited by 46
Self-citationLi, H., Chen, J., Li, Z., Chen, M., Ou, Z., Mo, M., Wang, R., Tong, S., Liu, P., Cai, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300110 · Cited by 49
Feng, B., Shen, Y., Hostench, X. P., Bieg, M., Plath, M., Ishaque, N., Eils, R., Freier, K., Weichert, W., Zaoui, K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3997 · Cited by 55
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
Zhang, W., Wang, P., & Pang, Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4625 · Cited by 64
PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas
Zhang, H., He, J., Dai, Z., Wang, Z., Liang, X., He, F., Xia, Z., Feng, S., Cao, H., Zhang, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.628966 · Cited by 62
“Previous work indicates that GEP and CYT are able to enhance anti-tumor activity and associated with the response to PD-1 inhibitor (49, 50).”
BackgroundZhang, W., Shi, F., Kong, Y., Li, Y., Sheng, C., Wang, S., & Wang, Q. (2021) · Cancer Medicine · doi:10.1002/cam4.4472 · Cited by 59
Wu, L., Zhang, Z., Bai, M., Yan, Y., Yu, J., & Xu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01139-8 · Cited by 53
Nazha, B., Zhuang, T., Wu, S. K., Brown, J. T., Magee, D., Carthon, B. C., Küçük, Ö., Nabhan, C., Barata, P. C., Heath, E. I., et al. (2023) · Cancer · doi:10.1002/cncr.34982 · Cited by 51
NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer
Hoshikawa, M., Aoki, T., Matsushita, H., Karasaki, T., Hosoi, A., Odaira, K., Fujieda, N., Kobayashi, Y., Kambara, K., Ohara, O., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.083 · Cited by 48
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
Belzile, O., Huang, X., Gong, J., Carlson, J., Schroit, A. J., Brekken, R. A., & Freimark, B. D. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s134834 · Cited by 49
Emerging Biomarkers in Cutaneous Melanoma
Eisenstein, A. S., Gonzalez, E. C., Raghunathan, R., Xu, X., Wu, M., McLean, E. O., McGee, J. S., Ryu, B., & Alani, R. M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0318-z · Cited by 52
CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade
Sato, Y., Bolzenius, J. K., Eteleeb, A. M., Su, X., Maher, C. A., Sehn, J. K., & Arora, V. K. (2018) · JCI Insight · doi:10.1172/jci.insight.121062 · Cited by 52
“In an integrated evaluation of clinical trials testing the PD-1 inhibitor pembrolizumab, IFN-γ signatures in pretreatment samples consistently correlated with clinical response (11).”
BackgroundLu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L., Xie, Z., Chen, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz3199 · Cited by 48
Tuo, Z., Zheng, X., Zong, Y., Li, J., Zou, C., Lv, Y., & Liu, J. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.6 · Cited by 48
Heimes, A.-S., Härtner, F., Almstedt, K., Krajnak, S., Lebrecht, A., Battista, M. J., Edlund, K., Brenner, W., Hasenburg, A., Şahin, U., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197178 · Cited by 50
Kim, H., Jeong, S., Park, S., Lee, Y. J., Ju, Y. S., Kim, D., Song, G., Lee, J. H., Kim, S., Shin, J., et al. (2021) · Liver International · doi:10.1111/liv.14814 · Cited by 51
Prognostic Potential of Tumor-Infiltrating Immune Cells in Resectable Oral Squamous Cell Carcinoma
Căruntu, A., Moraru, L., Lupu, M., Vasilescu, F., Dumitrescu, M., Cioplea, M. D., Popp, C. G., Dragusin, A. I., Căruntu, C., & Zurac, S. (2021) · Cancers · doi:10.3390/cancers13092268 · Cited by 48
T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model
Llewellyn, H. P., Arat, S., Gao, J., Wen, J., Xia, S., Kalabat, D., Oziolor, E., Virgen-Slane, R., Affolter, T., & Ji, C. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.037 · Cited by 47
Dinstag, G., Shulman, E. D., Elis, E., Ben-Zvi, D. S., Tirosh, O., Maimon, E., Meilijson, I., Elalouf, E., Temkin, B., Vitkovsky, P., et al. (2022) · Med · doi:10.1016/j.medj.2022.11.001 · Cited by 55
Type I interferon signature and cycling lymphocytes in macrophage activation syndrome
Huang, Z., Brodeur, K. E., Chen, L., Du, Wobma, H., Hsu, E. E., Liu, M., Chang, J. C. H., Chang, M. H., Chou, J. S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165616 · Cited by 55
Mei, T., Wang, T., & Zhou, Q. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01324-0 · Cited by 60
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Singh, H., Xiu, J., Kapner, K. S., Yuan, C., Narayan, R. R., Oberley, M. J., Farrell, A. P., Surana, R., Huffman, B. M., Perez, K. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1164 · Cited by 56
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Awada, G., Cascone, T., van der Heijden, M. S., Blank, C. U., Kok, M., & Chalabi, M. (2025) · Nature Cancer · doi:10.1038/s43018-025-00990-7 · Cited by 54
Chen, D., Jin, Z., Han, C., Wu, Y., Bian, Y., Yuan, T., Lv, H., Xia, Q., Wang, L., Chu, Q., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.014 · Cited by 52
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Romero-Cordoba, S. L., Meneghini, E., Sant, M., Iorio, M. V., Sfondrini, L., Paolini, B., Agresti, R., Tagliabue, E., & Bianchi, F. (2019) · Cancers · doi:10.3390/cancers11070911 · Cited by 50
The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice
Degoricija, M., Korać-Prlić, J., Vilović, K., Ivanišević, T., Haupt, B. E., Palada, V., Petković, M., Karaman, I., & Terzić, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02146-5 · Cited by 50
Frigola, J., Navarro, A., Carbonell, C., Callejo, A., Iranzo, P., Cedrés, S., Martínez‐Martí, A., Pardo, N., Gonzalez, N. S., Martinez, D., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12891 · Cited by 53
Zhu, Y., Elsheikha, H. M., Wang, J.-H., Fang, S., He, J.-J., Zhu, X.-Q., & Chen, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002970 · Cited by 51
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
Pirš, B., Škof, E., Smrkolj, V., & Smrkolj, Š. (2022) · Cancers · doi:10.3390/cancers14030631 · Cited by 52
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.